Intravenous Equipment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Intravenous (IV) Equipment Market is Segmented by Type (IV Catheters, Infusion Pumps, Securement Devices, Administration Sets, Drip Chambers, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD Million) for the Above Segments.

Intravenous (IV) Equipment Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Intravenous (IV) Equipment Market with other markets in Healthcare Industry

Intravenous (IV) Equipment Market Analysis by Mordor Intelligence

The IV therapy devices market size stands at USD 16.34 billion in 2025 and is projected to reach USD 22.07 billion by 2030, registering a 6.20% CAGR over the forecast period. Supply-chain fragility became clear when Hurricane Helene forced Baxter to shut its North Carolina plant, eliminating 60% of US IV fluid capacity and prompting hospitals to cut usage by up to 55%[1]Source: NPR Staff, “Hurricane Helene Shuts Baxter Plant And Triggers IV Fluid Shortage,” npr.org . The disruption accelerated point-of-care fluid production pilots and broadened calls for diversified sourcing. Regulatory pressure after multiple Class I recalls has pushed manufacturers toward AI-enabled safety features, driving rapid uptake of smart infusion systems. Asia-Pacific’s healthcare build-out and chronic-disease burden underpin the fastest regional expansion even as North America remains the revenue anchor. Intensifying M&A, illustrated by Stryker’s USD 4.9 billion acquisition of Inari Medical, signals a shift toward portfolio convergence that bundles pumps, catheters, and monitoring into integrated platforms.

Key Report Takeaways

  • By product type, IV catheters led with 38.34% of the IV therapy devices market share in 2024, whereas smart infusion pumps are forecast to deliver a 6.78% CAGR to 2030.
  • By end user, hospitals held 49.23% revenue share in 2024; home-care settings are expected to expand at a 7.12% CAGR through 2030.
  • By application, chemotherapy and oncology accounted for 7.89% CAGR growth, outpacing medication administration’s 44.45% revenue share baseline in 2024.
  • By geography, North America captured 42.23% of total revenue in 2024, while Asia-Pacific is projected to rise at an 8.12% CAGR between 2025 and 2030.

Segment Analysis

By Product Type: Smart Pumps Lead Innovation Wave

IV catheters controlled 38.34% of 2024 revenue as the foundational access tool across settings, securing the single-largest slice of the IV therapy devices market bbraunusa.com. Smart infusion pumps, however, represent the fastest growth at 6.78% CAGR thanks to AI dose-error reduction and cloud analytics. Baxter’s Spectrum IQ earned its seventh Best-in-KLAS award with 97% drug-library compliance, illustrating the performance bar now expected in the IV therapy devices market. Consumables such as tubing and administration sets benefit from steady replacement cycles, ensuring recurring revenue. Needle-free connectors, securement devices, and advanced filters collectively add infection-prevention value, making them attractive add-on sales. Mature drip-chamber components grow modestly yet remain essential, preserving backbone demand throughout the IV therapy devices market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End User: Home Care Disrupts Traditional Models

Hospitals retained 49.23% share in 2024, reflecting embedded procurement pathways and the scale of acute-care demand. Home-care settings, advancing at a 7.12% CAGR, illustrate how payer cost controls and patient comfort reorder priorities within the IV therapy devices market. Japanese home-care data show 21.6% of patients need intravenous therapy, yet 75% experience venous-access complications, spotlighting the safety gap that premium devices aim to close. Ambulatory surgery centers absorb spill-over cases as same-day procedures proliferate, requiring compact yet sophisticated pumps. Diagnostic and specialty clinics exploit niche oncology and immunology therapies where controlled infusion remains critical. Value-based care incentives further fuel migration outside hospitals, strengthening multi-setting demand across the IV therapy devices market.

By Application: Oncology Drives Premium Growth

Medication administration comprised 44.45% revenue in 2024, spanning antibiotics to biologics. Yet chemotherapy and oncology applications post the steepest climb at 7.89% CAGR, propelled by rising cancer incidence and regimen complexity. Closed-loop delivery prototypes like CLAUDIA monitor plasma drug levels every five minutes, foreshadowing a new standard of precision in the IV therapy devices market. Fluid and nutrition therapy retains baseline demand in critical-care units, while blood-product infusion requires strict alarm and monitoring features. AI-optimized parenteral nutrition formulations illustrate how application-specific software differentiation can unlock fresh value pools.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 42.23% of global revenue in 2024 owing to robust reimbursement and early technology adoption, reinforcing its anchor position in the IV therapy devices market. Yet Hurricane Helene exposed supply-chain risk, triggering federal initiatives to validate point-of-care fluid manufacturing and argue for broader supplier portfolios. Canada’s universal system and Mexico’s private-hospital build-out add incremental volumes, while a harmonizing regulatory backdrop facilitates cross-border trade.

Asia-Pacific is the fastest-growing region at an 8.12% CAGR, propelled by China’s healthcare-spend trajectory toward RMB 205 trillion by 2030 and incentive schemes that fast-track innovative devices . Japan’s super-aging society intensifies home-infusion uptake despite elevated complication rates, creating openings for safer vascular-access designs. India’s hospital expansion and chronic-disease surge position it as a high-potential adopter once reimbursement barriers ease. South Korea and Australia, with advanced payer systems, foster premium-device adoption that often cascades into neighboring markets, reinforcing Asia-Pacific’s strategic weight within the IV therapy devices market.

Europe delivers steady gains through stringent quality standards and sustainability mandates that spur eco-design innovation. Economic pressure in Southern markets dampens capital purchases, but Northern nations maintain high replacement cycles. Latin America and the Middle East & Africa contribute emerging-market upside: Brazil drives regional scale through public-hospital acquisitions, while GCC states channel oil revenues into specialty-care facilities requiring sophisticated IV infrastructure. South Africa acts as a distribution hub for sub-Saharan adoption. Collectively, these markets diversify revenue streams and cushion regional shocks for participants in the IV therapy devices market.

Intravenous (IV) Equipment Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The IV therapy devices market exhibits moderate consolidation, with the top five suppliers controlling majority of 2024 revenue. Strategic acquisitions characterize recent moves: BD paid USD 4.2 billion for Edwards Lifesciences’ critical-care assets to bundle monitoring with infusion delivery. Stryker’s USD 4.9 billion bid for Inari Medical secures entry into peripheral-vascular infusion therapies, signaling portfolio expansion beyond traditional orthopedics.

Regulatory stringency raises operating thresholds; smaller firms like InfuTronix exited after recalling 52,328 Nimbus units, underlining financial exposure to quality lapses. Platform strategies that integrate pumps, disposables, and analytics create sticky ecosystems that elevate switching costs for providers. AI capabilities now act as competitive differentiators: BD’s HemoSphere Alta showcases real-time cerebral-autoregulatory insights, whereas Baxter augments its Spectrum IQ with dose-change alerts.

White-space opportunities persist in home-infusion monitoring and mid-tier emerging markets where cost-optimized systems can undercut premium incumbents. Cybersecurity compliance and software-as-a-medical-device expertise are becoming critical gating factors for market entry. Collectively, these dynamics support healthy rivalry while reinforcing the importance of scale and technical depth within the IV therapy devices market.

Intravenous (IV) Equipment Industry Leaders

  1. Becton, Dickinson and Company

  2. 3M

  3. Henry Schein, Inc.

  4. B. Braun Melsungen AG

  5. ICU Medical, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Intravenous (IV) Equipment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: BD launched the HemoSphere Alta platform with AI-driven decision support for critical-care hemodynamics
  • April 2025: Teleflex secured FDA 510(k) clearance for the AC3 Range intra-aortic balloon pump
  • March 2025: Merck’s subcutaneous pembrolizumab met non-inferiority versus IV dosing in Phase 3 trial

Table of Contents for Intravenous (IV) Equipment Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising prevalence of chronic diseases requiring long-term IV therapy
    • 4.2.2 Growth in home- and ambulatory-based infusion therapy
    • 4.2.3 Increasing surgical procedures & hospitalization rates
    • 4.2.4 Technological advancements in smart infusion & needle-free systems
    • 4.2.5 Emergence of closed-loop AI drug-delivery algorithms
    • 4.2.6 Decentralized clinical trials driving portable IV devices
  • 4.3 Market Restraints
    • 4.3.1 Product recalls & medication-error related regulatory scrutiny
    • 4.3.2 High cost of advanced infusion systems in low-resource settings
    • 4.3.3 Shortage of skilled infusion nurses raising complication risks
    • 4.3.4 Shift toward subcutaneous/oral biologics reducing IV demand
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product Type
    • 5.1.1 Infusion Pumps
    • 5.1.2 IV Catheters (Peripheral & Central)
    • 5.1.3 Administration Sets & IV Tubing
    • 5.1.4 Securement & Stabilization Devices
    • 5.1.5 Needle-Free/Closed IV Connectors
    • 5.1.6 Drip Chambers & Filters
  • 5.2 By End User
    • 5.2.1 Hospitals & Clinics
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Home-Care Settings
    • 5.2.4 Diagnostic & Specialty Centers
  • 5.3 By Application
    • 5.3.1 Medication Administration
    • 5.3.2 Fluid & Nutrition Therapy
    • 5.3.3 Blood-based Products & Transfusions
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 South America
    • 5.4.4.1 Brazil
    • 5.4.4.2 Argentina
    • 5.4.4.3 Rest of South America
    • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Becton, Dickinson and Company
    • 6.3.2 B. Braun Melsungen AG
    • 6.3.3 Baxter International Inc.
    • 6.3.4 Fresenius SE & Co. KGaA
    • 6.3.5 ICU Medical, Inc.
    • 6.3.6 Smiths Medical
    • 6.3.7 Terumo Corporation
    • 6.3.8 Medtronic plc
    • 6.3.9 Nipro Corporation
    • 6.3.10 Teleflex Incorporated
    • 6.3.11 Cardinal Health
    • 6.3.12 Cook Medical
    • 6.3.13 Vygon SA
    • 6.3.14 Argon Medical Devices
    • 6.3.15 Moog Inc. (Medical)
    • 6.3.16 Mindray Medical International
    • 6.3.17 Hospira (Pfizer)
    • 6.3.18 JMS Co., Ltd.
    • 6.3.19 Smiths Group plc
    • 6.3.20 Braun Medical USA

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Intravenous (IV) Equipment Market Report Scope

IV administration means that the patient receives substances directly into their veins through a tube called a cannula. This could be either medication or nutrition. IV Therapy is a common practice for administering fluids to dehydrated patients, medications, chemotherapy treatments, and blood transfusions. 

The intravenous (IV) equipment market is segmented by type (IV catheters, infusion pumps, securement devices, administration sets, drip chambers, and other types), end-user (hospitals, ambulatory surgical centers, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. 

The report offers the value (in USD) for the above segments.

By Product Type Infusion Pumps
IV Catheters (Peripheral & Central)
Administration Sets & IV Tubing
Securement & Stabilization Devices
Needle-Free/Closed IV Connectors
Drip Chambers & Filters
By End User Hospitals & Clinics
Ambulatory Surgical Centers
Home-Care Settings
Diagnostic & Specialty Centers
By Application Medication Administration
Fluid & Nutrition Therapy
Blood-based Products & Transfusions
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
South America Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
By Product Type
Infusion Pumps
IV Catheters (Peripheral & Central)
Administration Sets & IV Tubing
Securement & Stabilization Devices
Needle-Free/Closed IV Connectors
Drip Chambers & Filters
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
Home-Care Settings
Diagnostic & Specialty Centers
By Application
Medication Administration
Fluid & Nutrition Therapy
Blood-based Products & Transfusions
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
South America Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the IV therapy devices market?

The IV therapy devices market size is USD 16.34 billion in 2025 and is projected to reach USD 22.07 billion by 2030 under a 6.20% CAGR.

Which product segment is expanding the fastest?

Smart infusion pumps lead growth at a 6.78% CAGR due to AI-enabled safety features and connectivity upgrades.

Why is Asia-Pacific viewed as the key growth region?

Rising healthcare spending, chronic-disease prevalence, and pro-innovation policies in China, India, and Japan push Asia-Pacific toward an 8.12% CAGR, the highest worldwide.

How are recalls influencing device innovation?

Heightened FDA scrutiny after Class I recalls compels manufacturers to embed AI dose-error checks, strengthen cybersecurity, and adopt ISO-aligned quality systems.

Will subcutaneous biologics erode future IV demand?

Large-volume subcutaneous formulations and oral biologics will lower some hospital infusions, yet complex chemotherapies and critical-care needs should sustain core IV volumes, especially for precision pumps.

Intravenous (IV) Equipment Market Report Snapshots